28 September 2018
Sure Ventures plc (“the Company”) is pleased to announce that it has raised gross proceeds of £1,078,480 pursuant to the Placing Programme, as described in the prospectus published on 17 November 2017 (“the Prospectus”). The Ordinary Shares have been issued at £1.0225 each, which after the costs and expenses of the issue represents a premium to the last published NAV per share of 96.17p per share.
Application has been made in respect of 1,054,748 Ordinary Shares to be admitted to trading on the Specialist Funds Segment of the Main Market of London Stock Exchange plc (“Admission”). Admission will become effective and dealings in the Ordinary Shares will commence at 8:00 a.m. (London time) on Wednesday 3 October 2018.
Following Admission, the Company will have 4,564,748 Ordinary Shares in issue. The total number of voting rights of the Company will be 4,564,748. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company.
Unless otherwise stated, capitalised terms used herein but not defined have the same meanings as set out in the Prospectus.
For further information, please contact:
Sure Ventures plc
0207 186 9900
Shard Capital Partners LLP
0207 186 9900
This announcement does not constitute or form part of, and should not be considered as, any offer for the sale or subscription of, or solicitation of any offer to buy or subscribe for, any shares in the Company or securities in any other entity, in any jurisdiction, including without limitation the United States, nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or investment decision whatsoever, in any jurisdiction. The announcement does not constitute a recommendation regarding any securities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.